DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
CLA
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CLA
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CARRAGEENAN
2
Unknown
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome; Conjunctivitis, Viral; Papillomavirus Infections
Unknown
CARRAGEENAN
×
Maximum Phase:
2
First Approval:
None
UNII:
5C69YCD2YJ
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FENEBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Urticaria; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
Tyrosine-protein kinase BTK inhibitor
FENEBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
E9L2885WUL
Molecule Type:
Small molecule
Molecular Formula:
C37H44N8O4
Molecular Weight:
664.81
AlogP:
3.57
PSA:
120.99
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BCX-1777
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BCX-1777
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
90Y-DOTA-HLL2
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
90Y-DOTA-HLL2
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZD-7268
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Unknown
AZD-7268
×
Maximum Phase:
2
First Approval:
None
UNII:
958Y70F3HQ
Molecule Type:
Small molecule
Molecular Formula:
C29H30N4O2S
Molecular Weight:
498.65
AlogP:
4.85
PSA:
69.56
HBD:
1.0
HBA:
#RotB:
7.0
Source:
CANTUZUMAB MERTANSINE
2
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
CANTUZUMAB MERTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
7Z7EUX7R6M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ERTEBEREL
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Hyperplasia; Schizophrenia
Estrogen receptor beta agonist
ERTEBEREL
×
Maximum Phase:
2
First Approval:
None
UNII:
2ZUL6758TZ
Molecule Type:
Small molecule
Molecular Formula:
C18H18O3
Molecular Weight:
282.34
AlogP:
4.12
PSA:
49.69
HBD:
2.0
HBA:
#RotB:
1.0
Source:
MIRICORILANT
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Non-alcoholic Fatty Liver Disease; Weight Gain
Unknown
MIRICORILANT
×
Maximum Phase:
2
First Approval:
None
UNII:
311Y5GV21M
Molecule Type:
Small molecule
Molecular Formula:
C24H23F3N2O2
Molecular Weight:
428.45
AlogP:
5.11
PSA:
65.72
HBD:
2.0
HBA:
#RotB:
4.0
Source:
BI 44370 TA
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BI 44370 TA
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAPABLURSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Thalassemia; beta-Thalassemia
Unknown
SAPABLURSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORNITHINE PHENYLACETATE
2
Small molecule
Investigational
Unknown
Unknown
Liver Cirrhosis; Liver Failure, Acute
Unknown
ORNITHINE PHENYLACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
9D6YZ105SN
Molecule Type:
Small molecule
Molecular Formula:
C13H20N2O4
Molecular Weight:
268.31
AlogP:
-0.86
PSA:
89.34
HBD:
3.0
HBA:
#RotB:
4.0
Source:
CP-724714
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasm Metastasis
Receptor protein-tyrosine kinase erbB-2 inhibitor
CP-724714
×
Maximum Phase:
2
First Approval:
None
UNII:
I05QZ0S4V3
Molecule Type:
Small molecule
Molecular Formula:
C27H27N5O3
Molecular Weight:
469.55
AlogP:
4.95
PSA:
98.26
HBD:
2.0
HBA:
#RotB:
9.0
Source:
ALVELESTAT
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Severe Acute Respiratory Syndrome; Bronchiectasis; Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive
Unknown
ALVELESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
6Y5629322X
Molecule Type:
Small molecule
Molecular Formula:
C25H22F3N5O4S
Molecular Weight:
545.54
AlogP:
3.29
PSA:
115.95
HBD:
1.0
HBA:
#RotB:
6.0
Source:
EP-100
2
Unknown
Investigational
Unknown
Unknown
Neoplasms; Ovarian Neoplasms
Cell membrane disrupting agent
EP-100
×
Maximum Phase:
2
First Approval:
None
UNII:
UF1EL37E41
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
M118
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
M118
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GOLOTIMOD
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C, Chronic; Stomatitis
Unknown
GOLOTIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
637C487Y09
Molecule Type:
Small molecule
Molecular Formula:
C16H19N3O5
Molecular Weight:
333.34
AlogP:
0.47
PSA:
145.51
HBD:
5.0
HBA:
#RotB:
8.0
Source:
(+)-EPICATECHIN
2
Small molecule
Investigational
Unknown
Unknown
Muscular Dystrophy, Duchenne; Prediabetic State; Friedreich Ataxia; Hypertension
Unknown
(+)-EPICATECHIN
×
Maximum Phase:
2
First Approval:
None
UNII:
LD6B6TT8Q5
Molecule Type:
Small molecule
Molecular Formula:
C15H14O6
Molecular Weight:
290.27
AlogP:
1.55
PSA:
110.38
HBD:
5.0
HBA:
#RotB:
1.0
Source:
ARX-788
2
Unknown
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
ARX-788
×
Maximum Phase:
2
First Approval:
None
UNII:
B2KH16FA7H
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABEDITEROL
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
ABEDITEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
QXA167CM6F
Molecule Type:
Small molecule
Molecular Formula:
C25H30F2N2O4
Molecular Weight:
460.52
AlogP:
4.23
PSA:
94.58
HBD:
4.0
HBA:
#RotB:
13.0
Source:
APRICOXIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Cyclooxygenase-2 inhibitor
APRICOXIB
×
Maximum Phase:
2
First Approval:
None
UNII:
5X5HB3VZ3Z
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O3S
Molecular Weight:
356.45
AlogP:
3.5
PSA:
74.32
HBD:
1.0
HBA:
#RotB:
5.0
Source:
ABC294640
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ABC294640
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
T-2000
2
Small molecule
Investigational
Unknown
Unknown
Essential Tremor
Unknown
T-2000
×
Maximum Phase:
2
First Approval:
None
UNII:
QW2J7VST60
Molecule Type:
Small molecule
Molecular Formula:
C20H20N2O5
Molecular Weight:
368.39
AlogP:
1.97
PSA:
76.15
HBD:
0.0
HBA:
#RotB:
6.0
Source:
EVATANEPAG
2
Small molecule
Investigational
Unknown
Unknown
Tibial Fractures
Prostanoid EP2 receptor agonist
EVATANEPAG
×
Maximum Phase:
2
First Approval:
None
UNII:
L266R6E31E
Molecule Type:
Small molecule
Molecular Formula:
C25H28N2O5S
Molecular Weight:
468.58
AlogP:
4.23
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
9.0
Source:
L-SULFORAPHANE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
L-SULFORAPHANE
×
Maximum Phase:
2
First Approval:
None
UNII:
7J94TPZ10L
Molecule Type:
Small molecule
Molecular Formula:
C6H11NOS2
Molecular Weight:
177.29
AlogP:
1.25
PSA:
29.43
HBD:
0.0
HBA:
#RotB:
5.0
Source:
CD24FC
2
Unknown
Investigational
Unknown
Unknown
Melanoma; Neoplasms; Severe Acute Respiratory Syndrome
Heat shock 70 kDa protein 1A/1B inhibitor
CD24FC
×
Maximum Phase:
2
First Approval:
None
UNII:
FN12T66RMN
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KOS-1584
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Tubulin stabiliser
KOS-1584
×
Maximum Phase:
2
First Approval:
None
UNII:
82481G197K
Molecule Type:
Small molecule
Molecular Formula:
C27H39NO5S
Molecular Weight:
489.68
AlogP:
5.04
PSA:
96.72
HBD:
2.0
HBA:
#RotB:
2.0
Source:
VALATEGRAST
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Unknown
VALATEGRAST
×
Maximum Phase:
2
First Approval:
None
UNII:
06DM4KX7JG
Molecule Type:
Small molecule
Molecular Formula:
C30H32Cl3N3O4
Molecular Weight:
604.96
AlogP:
6.43
PSA:
87.74
HBD:
2.0
HBA:
#RotB:
12.0
Source:
DIMETHYLAMINOETHANOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DIMETHYLAMINOETHANOL
×
Maximum Phase:
2
First Approval:
None
UNII:
2N6K9DRA24
Molecule Type:
Small molecule
Molecular Formula:
C4H11NO
Molecular Weight:
89.14
AlogP:
-0.46
PSA:
23.47
HBD:
1.0
HBA:
#RotB:
2.0
Source:
LUCATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma
Tumor necrosis factor receptor superfamily member 5 antagonist
LUCATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
P0EP9VFC4R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GRANOTAPIDE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
GRANOTAPIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
PSZ2YGB0DK
Molecule Type:
Small molecule
Molecular Formula:
C39H37F3N2O8
Molecular Weight:
718.73
AlogP:
6.48
PSA:
128.31
HBD:
1.0
HBA:
#RotB:
13.0
Source:
PROCYSTEINE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
PROCYSTEINE
×
Maximum Phase:
2
First Approval:
None
UNII:
X7063P804E
Molecule Type:
Small molecule
Molecular Formula:
C4H5NO3S
Molecular Weight:
147.16
AlogP:
-0.1
PSA:
66.4
HBD:
2.0
HBA:
#RotB:
1.0
Source:
PALMIDROL
2
Small molecule
Investigational
Unknown
Unknown
Tourette Syndrome
Unknown
PALMIDROL
×
Maximum Phase:
2
First Approval:
None
UNII:
6R8T1UDM3V
Molecule Type:
Small molecule
Molecular Formula:
C18H37NO2
Molecular Weight:
299.5
AlogP:
4.58
PSA:
49.33
HBD:
2.0
HBA:
#RotB:
16.0
Source:
CHOLESTEROL
2
Small molecule
Investigational
Unknown
Unknown
Asperger Syndrome; Autistic Disorder; Head and Neck Neoplasms; Porokeratosis; Smith-Lemli-Opitz Syndrome
Unknown
CHOLESTEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
97C5T2UQ7J
Molecule Type:
Small molecule
Molecular Formula:
C27H46O
Molecular Weight:
386.66
AlogP:
7.39
PSA:
20.23
HBD:
1.0
HBA:
#RotB:
5.0
Source:
EGFR
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
EGFR
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
142
143
144
145
146
147
148
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA